<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ursodeoxycholic acid (ursodiol): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ursodeoxycholic acid (ursodiol): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ursodeoxycholic acid (ursodiol): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10033" href="/d/html/10033.html" rel="external">see "Ursodeoxycholic acid (ursodiol): Drug information"</a> and <a class="drug drug_patient" data-topicid="11900" href="/d/html/11900.html" rel="external">see "Ursodeoxycholic acid (ursodiol): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F232635"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Actigall [DSC];</li>
<li>Reltone;</li>
<li>Urso 250;</li>
<li>Urso Forte</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868546"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Ursodiol;</li>
<li>GLN-Ursodiol;</li>
<li>JAMP-Ursodiol;</li>
<li>PMS-Ursodiol;</li>
<li>PMS-Ursodiol C;</li>
<li>Urso DS [DSC];</li>
<li>Urso [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062826"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gallstone Dissolution Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462614"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Extemporaneously compounded oral suspensions are available in multiple concentrations (eg, 20 mg/mL, 25 mg/mL, 50 mg/mL, 60 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg of ursodiol (ie, not in mL or number of tablets).<b></b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20b45f57-1b47-4a7b-b4d0-bbd425b03414">Biliary atresia, status post-Kasai procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary atresia, status post-Kasai procedure:</b> Limited data available: Term neonates: Usual dose: Oral: 10 to 20 mg/kg/day in 2 to 3 divided doses. Dosing based on small prospective and retrospective trials of neonates and very young infants that included ursodiol as part of a multidrug regimen designed to reduce the risk of cholangitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17878208','lexi-content-ref-12632357','lexi-content-ref-2730950','lexi-content-ref-17706489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17878208','lexi-content-ref-12632357','lexi-content-ref-2730950','lexi-content-ref-17706489'])">Ref</a></span>). Some centers have reported higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30130826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30130826'])">Ref</a></span>); a range of 20 to 36 mg/kg/day (mean: 25 mg/kg/day) in divided doses was reported in neonates and infants (n=16) following Kasai procedures at a median age of 54 days (range: 14 to 89 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19029197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19029197'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58e4a5bb-8583-4ee1-aa96-e39c3d4a3366">Parenteral nutrition-induced cholestasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition-induced cholestasis: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Efficacy results variable: Preterm and term neonates: Reported range: Oral: 10 to 30 mg/kg/day in 3 divided doses; dosing based on reported retrospective studies that included preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15343182','lexi-content-ref-10417972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15343182','lexi-content-ref-10417972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates who were treated with ursodiol had a significantly shortened duration of cholestasis (62.8 ± 10.7 days vs 92.4 ± 8.8 days) and decreased peak direct bilirubin (5.3 ± 0.6 mg/dL vs 8.7 ± 1.1 mg/dL) compared to no treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15343182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15343182'])">Ref</a></span>); improvement of bilirubin was seen after 2 weeks and 50% of patients saw a decrease in transaminases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10417972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10417972'])">Ref</a></span>). However, in another large retrospective trial (n=64), neonates receiving ursodiol (mean dose: 24.9 mg/kg/day) had a significantly prolonged resolution of cholestasis compared to controls (median: 79 vs 50 days); authors attribute this to smaller, more premature patients in the treatment group and possibly due to a delay in treatment with ursodiol (time from onset of cholestasis to treatment: median: 24 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24782691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24782691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> Reported regimens variable: Preterm neonates: Oral: 20 to 25 mg/kg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18223390','lexi-content-ref-21566568','lexi-content-ref-34988851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18223390','lexi-content-ref-21566568','lexi-content-ref-34988851'])">Ref</a></span>). In a randomized, placebo-controlled trial of 102 preterm neonates (n=42 treatment group), ursodiol doses of 20 to 25 mg/kg/day in 2 divided daily doses were shown to significantly prevent neonatal cholestasis (0% vs 11.7%) with significantly lower peak direct and total bilirubin levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34988851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34988851'])">Ref</a></span>). In a smaller prospective, randomized, controlled study of neonates who received parenteral nutrition for at least 12 days and were receiving &lt;75 mL/kg/day of enteral feeds by day of life 14, 24 neonates received ursodiol at 20 mg/kg/day in 4 divided doses starting at day of life 14; results showed ursodiol was more effective at preventing cholestasis compared to erythromycin or placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21566568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21566568'])">Ref</a></span>). Dose titration was reported in a double-blind, placebo-controlled study of 15 premature neonates requiring parenteral nutrition during the first few days of life; ursodiol was initiated at 5 mg/kg/day in 4 divided doses beginning on day of life 3 with initiation of parenteral nutrition; increase dose to 10 mg/kg/day in 4 divided doses with initiation of enteral feeding; increase dose to 20 mg/kg/day in 4 divided doses when full enteral feedings reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18223390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18223390'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812561"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Extemporaneously compounded oral suspensions are available in multiple concentrations (eg, 20 mg/mL, 25 mg/mL, 50 mg/mL, 60 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg of ursodiol (ie, not in mL or number of tablets).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20b45f57-1b47-4a7b-b4d0-bbd425b03414">Biliary atresia, status post-Kasai procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary atresia, status post-Kasai procedure:</b> Limited data available: Infants and Children: Oral: 10 to 20 mg/kg/day in 2 to 3 divided doses. Dosing based on small prospective and retrospective trials that included ursodiol as part of a multidrug regimen designed to reduce the risk of cholangitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17878208','lexi-content-ref-12632357','lexi-content-ref-2730950','lexi-content-ref-17706489','lexi-content-ref-8201513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17878208','lexi-content-ref-12632357','lexi-content-ref-2730950','lexi-content-ref-17706489','lexi-content-ref-8201513'])">Ref</a></span>). Some patients may require higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30130826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30130826'])">Ref</a></span>); a range of 20 to 36 mg/kg/day (mean: 25 mg/kg/day) in divided doses was reported in neonates and infants (n=16) following Kasai procedures at a median age of 54 days (range: 14 to 89 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19029197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19029197'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1ee9212-b2f2-4e8e-a9ec-f82029e1f3bb">Cystic fibrosis-related liver disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis-related liver disease:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 20 mg/kg/day in 2 divided doses; reported range: 10 to 30 mg/kg/day in divided doses; individualize dose based on patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2391610','lexi-content-ref-21658639','lexi-content-ref-22670841','lexi-content-ref-9003851','lexi-content-ref-9934970','lexi-content-ref-Warner.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2391610','lexi-content-ref-21658639','lexi-content-ref-22670841','lexi-content-ref-9003851','lexi-content-ref-9934970','lexi-content-ref-Warner.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="140da939-d777-4801-a498-a19c98f47bca">Parenteral nutrition-induced cholestasis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition-induced cholestasis, treatment:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24696095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24696095'])">Ref</a></span>): Infants and Children: Oral: 30 mg/kg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15343182','lexi-content-ref-16842466','lexi-content-ref-8780577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15343182','lexi-content-ref-16842466','lexi-content-ref-8780577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0437d64a-6e4d-4b96-8f99-82c938b34d8f">Pruritus secondary to cholestasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus secondary to cholestasis:</b> Limited data available: Infants, Children, and Adolescents: Oral: 15 to 20 mg/kg/day once daily or in divided doses twice daily; doses up to 30 mg/kg/day may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10770681','lexi-content-ref-Hassan.1','lexi-content-ref-9443120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10770681','lexi-content-ref-Hassan.1','lexi-content-ref-9443120'])">Ref</a></span>). Dosing based on long-term (2.5 years), open-label, crossover trial of 13 patients (ages 2 to 27 years) with intrahepatic cholestasis; six of the 13 patients had symptomatic improvement in pruritus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9443120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9443120'])">Ref</a></span>). In another study of 24 pediatric patients (1.5 to 15 years) treated with ursodiol, all patients experienced improvement in pruritus and 16.7% had complete resolution of pruritus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10770681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10770681'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0749c606-2471-42e8-820b-8ba6719d54fa">Veno-occlusive disease following hematopoietic stem cell transplantation, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Veno-occlusive disease (sinusoidal obstruction syndrome) following hematopoietic stem cell transplantation, prevention: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27892944','lexi-content-ref-32091825','lexi-content-ref-31818728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27892944','lexi-content-ref-32091825','lexi-content-ref-31818728'])">Ref</a></span>); efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26017019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26017019'])">Ref</a></span>); reported dosing regimens variable; initiate during conditioning phase; refer to specific protocols:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Usual reported range: 10 to 15 mg/kg/day in 2 divided doses; some centers have used doses up to 30 mg/kg/day; if a solid dosage form appropriate for the patient, doses may be rounded to next available dosage form (eg, 150 mg tablet); maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30266674','lexi-content-ref-31214465','lexi-content-ref-35468945','lexi-content-ref-12200355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30266674','lexi-content-ref-31214465','lexi-content-ref-35468945','lexi-content-ref-12200355'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729862"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729863"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F232639"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10033" href="/d/html/10033.html" rel="external">see "Ursodeoxycholic acid (ursodiol): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c094826a-cdf0-4c2a-9f84-dad10fcb7c49">Gallstone dissolution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone dissolution (capsules):</b>
<b>Oral:</b> 8 to 10 mg/kg/day in 2 to 3 divided doses; use beyond 24 months is not established.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b5cd657-8529-496e-9cf2-d27235e4bb29">Gallstone prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone prevention (capsules):</b>
<b>Oral:</b> 600 mg/day in 1 or 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b50f2eb6-428f-4a6b-ae7c-758e07f3e937">Gallstone prevention post–bariatric surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone prevention post–bariatric surgery (off-label use):</b>
<b>Oral:</b> 500 to 600 mg once daily or in 2 divided doses for 6 months. <b>Note:</b> Doses up to 1,200 mg/day were effective but were associated with a higher incidence of nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28889240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28889240'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf543bee-1199-4075-9f53-5648d688dd4b">Hepatic sinusoidal obstruction syndrome associated with stem cell transplant, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic sinusoidal obstruction syndrome associated with stem cell transplant, prevention (off-label use): Oral: </b>12 mg/kg/day in 2 divided doses beginning 1 day before the conditioning regimen and continuing for 90 days after transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12200355','lexi-content-ref-24141008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12200355','lexi-content-ref-24141008'])">Ref</a></span>). Refer to institutional protocols for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="366ebe72-49b0-4a85-9095-575d4f1c4b05">Intrahepatic cholestasis of pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrahepatic cholestasis of pregnancy (off-label use): Oral:</b> 10 to 15 mg/kg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26832651','lexi-content-ref-33197417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26832651','lexi-content-ref-33197417'])">Ref</a></span>) or 500 mg twice daily, gradually increase in increments of 500 mg/day (range: 500 mg to 2,000 mg/day in divided doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31378395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31378395'])">Ref</a></span>); continue until delivery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67c68882-4ee6-4f70-a55c-feecc907f736">Primary biliary cholangitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary biliary cholangitis (tablets):</b>
<b>Oral:</b> 13 to 15 mg/kg/day in 2 to 4 divided doses (with food). <b>Note:</b> May be given once daily (at bedtime) to improve compliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ccc8b353-2ca7-4f4d-80c9-9693992d24dd">Primary sclerosing cholangitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary sclerosing cholangitis (off-label use): Note:</b> May be considered in patients who are not interested in clinical trial enrollment with persistently elevated alkaline phosphatase for at least 6 months prior to initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36083140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36083140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> 13 to 23 mg/kg/day in 2 to 4 divided doses; continue as tolerated if there is a reduction or normalization in alkaline phosphatase and/or improvement in symptoms with 12 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36083140','lexi-content-ref-9041099','lexi-content-ref-16285948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36083140','lexi-content-ref-9041099','lexi-content-ref-16285948'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991934"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;1% excreted in urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (mainly distributed in bile and small intestine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (mainly distributed in bile and small intestine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989190"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58253803"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Enteroliths</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ursodeoxycholic acid (UDCA) will precipitate from water at a pH of 8 to 8.1, and its glycine conjugated form will precipitate from water at a pH of 6.5 to 7.4 and 37ºC (98ºF), which may lead to crystalline formation within bile ducts (pH 6.5 to 8) or within the small intestine lumen (pH 6 to 8) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008','lexi-content-ref-1619357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008','lexi-content-ref-1619357'])">Ref</a></span>). UDCA crystals are postulated to provide a base for enterolith/stone formation, and recurrent exposure allows additional precipitation and formation of the UDCA based enteroliths/stones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008'])">Ref</a></span>). UDCA based enteroliths/stones can lead to obstruction, localized inflammation and infection and may recur with continued use of UDCA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008','lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008','lexi-content-ref-25091893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; likely related to the use of UDCA in the setting of conditions in which UDCA and its conjugated metabolites are exposed to an acidic environment, following liver first pass metabolism, for a prolonged period leading to precipitation of the conjugated metabolites or parent drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008','lexi-content-ref-1619357','lexi-content-ref-34746509','lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008','lexi-content-ref-1619357','lexi-content-ref-34746509','lexi-content-ref-25091893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (ie, occurs after 30 days of drug therapy); case reports suggest may occur as early as 1 to 2 months after drug initiation or may take several months to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008','lexi-content-ref-34746509','lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008','lexi-content-ref-34746509','lexi-content-ref-25091893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Recurrent biliary infection (eg, recurrent cholangitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of gastrointestinal surgery with surgical anastomosis that allows for free communication between the gastrointestinal and biliary tracts (eg, choledochoduodenostomy, Roux-en-Y hepaticojejunostomy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008','lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008','lexi-content-ref-25091893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired intestinal flow (bowel stasis) due to a blind loop or adhesions resulting as a complication of gastrointestinal surgery, especially in patients who undergo reoperation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25091893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of gastric acid suppression (eg, proton pump inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25366008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25366008'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of intestinal stenosis (eg, proximal small intestine) associated with inflammatory bowel disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34746509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34746509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant immunosuppression which may enhance bacterial overgrowth in the small intestine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25091893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25091893'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F232610"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (10% to 26%), diarrhea (1% to 27%), dyspepsia (3% to 17%), nausea (5% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (17%), headache (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (12% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (5%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis (5%), peptic ulcer (1%), vomiting (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (3%), thrombocytopenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (6%), musculoskeletal pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (7%), cough (7%), flu-like symptoms (7%), pharyngitis (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, esophagitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous System: Asthenia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, bezoar formation</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F232624"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ursodiol or any component of the formulation (tablet); not to be used with calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones; patients with unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula; allergy to bile acids</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Complete biliary obstruction of extrahepatic origin; widespread intrahepatic obstruction</p></div>
<div class="block war drugH1Div" id="F232607"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary obstruction: Maintain bile flow during therapy to prevent biliary obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Use with caution in patients with chronic liver disease. Monitor LFTs; consider discontinuing therapy in patients with significant elevations in LFTs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Gallbladder stone dissolution may take several months of therapy; complete dissolution may not occur and recurrence of stones within 5 years has been observed in up to 50% of patients. Patients should be cautiously selected for therapy, consider alternative treatments. Specific treatments should be initiated in patients with ascites, hepatic encephalopathy, variceal bleeding, or if an urgent liver transplant is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nonvisualizing gallbladder: Use with caution in patients with a nonvisualizing gallbladder; therapy should be discontinued if gallbladder nonvisualization occurs during treatment.</p></div>
<div class="block foc drugH1Div" id="F232618"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actigall: 300 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Reltone: 200 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Reltone: 400 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Urso 250: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Urso Forte: 500 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F232603"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F232626"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Reltone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $23.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $35.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ursodiol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $50.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.50 - $13.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $70.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Urso 250 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $6.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Urso Forte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $11.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ursodiol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868547"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Urso: 250 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Urso DS: 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block exp drugH1Div" id="F232622"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>60 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 60 mg/mL ursodiol oral suspension may be made with capsules. Empty the contents of twelve 300 mg capsules into a mortar. Add small portions of glycerin and mix to a uniform paste; mix while adding simple syrup in incremental proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well" and "refrigerate". Stable for 35 days refrigerated (Johnson 1995).</p>
<div class="reference">Johnson CE, Nesbitt J. Stability of ursodiol in an extemporaneously compounded oral liquid. <i>Am J Health Syst Pharm.</i> 1995;52(16):1798-1800.<span class="pubmed-id">8528836</span></div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>20 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 20 mg/mL ursodiol oral suspension may be made with capsules and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of methylcellulose 1% and syrup NF. Empty the contents of seventeen 300 mg capsules into a mortar. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 255 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 255 mL. Label "shake well" and "refrigerate". Stable for 91 days refrigerated (Nahata 1999).</p>
<div class="reference">Nahata MC, Morosco RS, Hipple TF. Stability of ursodiol in two extemporaneously prepared oral suspensions. <i>J Appl Ther Res. </i>1999;2:221-224.</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>25 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 25 mg/mL ursodiol oral suspension may be made with capsules. Empty the contents of ten 300 mg capsules into a mortar; add 10 mL Glycerin, USP and mix until smooth. Mix while adding 60 mL Ora-Plus; transfer mixture to a light-resistant bottle, rinse mortar with a small amount of Orange Syrup, NF, and add quantity of syrup sufficient to make 120 mL. Label "shake well". Stable for 60 days at room temperature or refrigerated (Mallett 1997).</p>
<div class="reference">Mallett MS, Hagan RL, Peters DA. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid. <i>Am J Health Syst Pharm.</i> 1997;54(12):1401-1404.<span class="pubmed-id">9194984</span></div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>50 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 50 mg/mL ursodiol oral suspension may be made with tablets and 60 mL of either a 1:1 mixture of Ora-Plus and strawberry syrup or a 1:1 mixture of Ora-Plus and Ora-Sweet SF. Crush twelve 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well" and "refrigerate". Stable for 90 days refrigerated (Johnson 2002).</p>
<div class="reference">Johnson CE, Streetman DD. Stability of oral suspensions of ursodiol made from tablets. <i>Am J Health Syst Pharm.</i> 2002;59(4):361-363.<span class="pubmed-id">11885400</span></div>
</div>
<div class="block admp drugH1Div" id="F52613991"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not administer with aluminum-based antacids or bile acid sequestrants. If aluminum-based antacids are needed, administer 2 hours after ursodiol; administer ursodiol 5 hours or more after bile acid sequestrants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10651838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10651838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Urso Forte can be split into halves for appropriate dosage; do not chew. Urso and Urso Forte should be administered with food.</p></div>
<div class="block adm drugH1Div" id="F803233"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Do not administer with aluminum-based antacids or bile acid sequestrants. If aluminum-based antacids are needed, administer 2 hours after ursodiol; some experts recommend administering ursodiol 1 hour prior to or 4 to 5 hours after bile acid sequestrants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375','lexi-content-ref-10651838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375','lexi-content-ref-10651838'])">Ref</a></span>). Urso Forte can be split into halves for appropriate dosage; do not chew. Tablets should be taken with food.</p></div>
<div class="block sts drugH1Div" id="F232632"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Urso: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Urso Forte: Store at 20°C to 25°C (68°F to 77°F). When broken in half, scored Urso Forte 500 mg tablets maintain quality for up to 28 days when kept in current packaging and stored at 20°C to 25°C (68°F to 77°F). Split tablets should be stored separately from whole tablets due to bitter taste.</p></div>
<div class="block usep drugH1Div" id="F53569394"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Gallbladder stone dissolution for patients with radiolucent, noncalcified gallbladder stones &lt;20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk caused by systemic disease, advanced age, or idiosyncratic reaction to general anesthesia, or for patients who refuse surgery; prevention of gallstone formation in obese patients experiencing rapid weight loss (All indications: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Treatment of primary biliary cirrhosis (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used to facilitate bile excretion in infants with biliary atresia, treat cholestasis secondary to parenteral nutrition (PN), aid fat absorption in cystic fibrosis-related liver disease, and prevent veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) following hematopoietic stem cell transplantation.</p></div>
<div class="block mst drugH1Div" id="F10579627"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ursodiol may be confused with ulipristal</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300198"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223602"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Ursodiol. Management: Separate administration of ursodiol and aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Ursodiol. Management: Administer ursodiol 1 hour before or at least 4 to 5 hours after bile acid sequestrants to minimize the potential for any significant interaction. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Ursodiol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: Ursodiol may decrease the absorption of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F232627"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Urso and Urso Forte should be taken with food.</p></div>
<div class="block pri drugH1Div" id="F13966873"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ursodiol has been evaluated for treating intrahepatic cholestasis of pregnancy (ICP). Maternal symptoms (eg, itching, increased bile acid concentrations) generally occur during the second and third trimester. Fetal distress, preterm birth, and intrauterine death are also associated with ICP. Although some studies have shown a decrease in maternal symptoms (primarily itching) with ursodiol treatment, data is inconclusive regarding improvement of fetal/neonatal outcomes (ACG [Tran 2016]; Chappell 2019; Kong 2016; Ovadia 2021; Parízek 2016; Sepúlveda Marín 2016; Shen 2019; SMFM [Lee 2021]; Walker 2020; Zhang 2016).</p>
<p style="text-indent:0em;margin-top:2em;">The American College of Gastroenterology guideline for liver disease in pregnancy and the Society for Maternal-Fetal Medicine intrahepatic cholestasis of pregnancy consult series consider ursodiol a first-line therapy for the treatment of ICP during the second and third trimesters of pregnancy (ACG [Tran 2016]; SMFM [Lee 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53569390"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic disease: Monitor liver function tests (GGT, AST, ALT, bilirubin, and alkaline phosphatase) monthly for the first 3 months and every 6 months thereafter or as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Gallbladder disease: ALT, AST, sonogram.</p></div>
<div class="block pha drugH1Div" id="F232606"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ursodiol decreases the cholesterol content of bile and bile stones by reducing the secretion of cholesterol from the liver and the fractional reabsorption of cholesterol by the intestines. Mechanism of action in primary biliary cholangitis is not clearly defined. Ursodiol reduces hydrophobic bile acids; hydrophobic bile acids may be toxic to hepatic parenchymal cells in patients receiving hematopoietic stem cell transplantation (BCSH/BSBMT [Dignan 2013]; Ruutu 2002).</p></div>
<div class="block phk drugH1Div" id="F232623"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 90% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Undergoes extensive enterohepatic recycling; following hepatic conjugation and biliary secretion, the drug is hydrolyzed to active ursodiol, where it is recycled or transformed to lithocholic acid by colonic microbial flora; during chronic administration, ursodiol becomes a major biliary and plasma bile acid constituting 30% to 50% of biliary and plasma bile acids</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces; urine (&lt;1%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F232628"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ursobil | Ursofalk | Ursosan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dexo | Solutrat | Udca | Urdecole | Urigesic | Ursidesox | Ursodiol | Ursofalk | Ursomax | Ursotop | Urzac | Urzac Forte | Utral</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursogrix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ursodeoxycholic acid apotex | Ursodox gh | Ursofalk | Ursosan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Antigall | Liconor | Liveric | Oxycol | Stener | Stonex | Udca | Udihep | Urso | Ursocol | Ursodex | Ursodil | Ursolic | Ursoren</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dozurso | Ursochol | Ursofalk</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Choludexan | Ursofalk</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acido ursodesoxicolico | Duxio | Gulshen | Ursacol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">De-ursil | De-ursil rr | Ursochol | Ursodiol rr zentiva | Ursodiol zentiva | Ursofalk</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cholurso | Urlyx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Solvobil | Ursofalk</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ursodeoxycholic ac | Ursofalk</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Litomen | Ursacol | Ursofalk | Ursox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursogrix | Ursonorm | Ursosan | Ursosan forte</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cholacid | Cholofalk | Udc | Urso | Urso 1a pharma | Urso heumann | Ursochol | Ursofalk | Ursonorm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">UDCA Ferring | Ursacol | Ursofalk</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ursocel | Ursofalk</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ursogrix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Biliver | Egyurso | Exosirylic | Galldepedra | Livagoal | Udexpan | Ursochol | Ursocholic | Ursodiol | Ursodol | Ursofalk | Ursogall | Ursosernox | Ursotwin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adisocol | Bilifalk | Ursobilane | Ursochol | Ursolite</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ursoliv</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adursal | Ursochol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide ursodesoxycholique arrow | Acide ursodesoxycholique biogaran | Acide ursodesoxycholique mylan | Acide ursodesoxycholique teva | Arsacol | Cholurso | Delursan | Dozurso | Tillhepo | Ursolvan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cholurso | Destolit | Urdox | Ursodeoxychol | Ursodeoxychol acid | Ursofalk | Ursogal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pms-ursodiol C | Uldeso | Ursodex | Ursofalk | Ursolvan | Ursosan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Estazor | Lofibra | Pramur | Urdafalk | Urdahex | Urdex | Ursochol | Ursolic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Destolit | Ursodeoxycholic acid strides | Ursofalk</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ursolit</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actibile | Aliveon | Analiv Ud | Bilefix | Cholidol | Estuchol | Fortibile | Gb liv | Gemiuro | Golbi | Hepakind | Hepexa | Levalon | Livanza | Livokind | Livolysin | Livopill ud | Movebile | Open up | Otraliv | Sedogest | Shinoliv | Solubid | Sorbidiol | U.d.c.a. | Uclick | Uda | Udc | Udchamp | Udcoliv | Udcros | Udebile | Udgrace | Udichol | Udigold | Udigrand | Udihep | Udilink | Udiliv | Udimorr | Udiron | Udivor | Udoxyl | Udxic | Ulyses | Urdiogem | Urdohep | Uricure | Urijon | Urosec | Urs | Ursetor | Ursobiac | Ursocol | Ursodil | Ursodin | Ursodox | Ursodox sr | Ursofalk gr | Ursoford | Ursokem | Ursol | Ursolic | Ursolid | Ursomax | Ursonem | Ursopro | Ursowin | Usibon | Xdator</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ac ursod | Ac ursod eg | Biliepar | Coledos | Desocol | Desoxil | Deursil | Deursil rr | Dissolursil | Dozurso | Fraurs | Lentorsil | Litoff | Litursol | Urdes | Ursacol | Ursilon | Ursobil | Ursobil ht | Ursodamor | Ursodiol | Ursofalk | Ursoflor | Ursolac | Ursolisin | Urson</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ursa | Ursofalk</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Buraue | Chymotamine | Gokumisin | Precoat | Reptor | Rusorol | Shikichol | Ubiron | Urdenacin | Urdeston | Urdex | Ursamic | Urso mitsubishi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Udihep | Udihep forte | Ursocol | Ursoliv</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ciraedan | Daewoongbio ursodeoxycholic acid | Ganeu | Ganmoru | Liverstal | Sulgidam Freshmint | Sulgidam rose | Udca | Udese | Udici | Ugimax | Urchol | Uro | Ursa | Ursofalk | Urucom | Uruliver | Urusa | Usosan | Wookiton</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ursobil | Ursofalk</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursogrix | Ursosan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ursochol | Ursofalk</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursogrix | Ursosan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido ursodeoxicolico | Coric | Durcox | Kyselin | Nilamsel | Prestalix au | T ruxico | Tripsix | Udca | Urlodil | Ursofalk | Xifhac</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Grinterol | Udca | Ursochol | Ursodeoxycholzuur | Ursodeoxycholzuur glenmark | Ursodeoxycholzuur Imphos | Ursodeoxycholzuur Sandoz | Ursodeoxycholzuur strides | Ursofalk | Ursonorm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Destolit | Ursochol | Ursodeoxycholic acid orion | Ursofalk</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Actigall | Ursofalk | Ursosan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clotipide | Coleretik | Urdecole | Ursobil | Ursocel | Ursofalk | Ursoflow</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actibile | Ambisol | Axialith | Choledeo | Destone | Lupibile | Udcacid | Urlyx | Urodil | Ursa | Ursential | Ursodox | Ursofalk | Ursolin | Ursoliv | Ursomax | Ursotrol | Ursula | Usosan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bilcid | Biledox | Bilex | Bilex forte | Calculix | Cholistone | Galbil | Triptor | Udca | Urolic | Urso | Ursochole | Ursodil | Ursodol | Ursofalk | Ursohep | Ursolic | Ursomax | Ursoton | Ursowin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biliepar | Proursan | Ursocam | Ursofalk | Ursopol | Ursoxyn</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Actigall | Reltone | Urso | Urso forte | Ursodiol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Destolit | Ursofalk</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dexo | Solutrat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ursochol | Ursofalk | Ursorom | Ursosan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Choludexan | Ekurokhol | Exhol | Grinterol | Livodexa | Protecholin | Urbihol | Urcevel | Urdoxa | Ursodeoxychol acid | Ursodex | Ursodez | Ursodiolisin | Ursofalk | Ursolit | Ursoliv | Ursomax | Ursomic | Ursorom C | Ursorom rompharm | Ursosan | Ursosan forte</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pms-ursodiol C | Urdox | Ursodiol | Ursofalk</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ursochol | Ursodeoxycholic acid orion | Ursofalk | Ursogrix | Ursosan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursolvan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursosan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursogrix | Ursomed | Ursosan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cholemax | Udihep | Ursa | Urso | Ursode | Ursofalk | Ursolin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ursobilane | Ursolvan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Deoxykol | Proursan | Safrax | Ursabay | Ursactive | Ursodin | Ursofalk | Ursomed | Ursovef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Biliepar | Cisbile | Genurso | Gokumisin | Legan | Ligat | Lipo | Sodan | Uliden | Uliso | Urose | Uroso | Urso | Ursocid | Ursodesoxycholic acid | Ursol | Ursolic | Usol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Choludexan | Grinterol | Ukrliv | Ursochol | Ursodiol | Ursofalk | Ursolisin | Ursonost | Ursosan | Ursosan forte</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Udihep | Udihep forte | Ursoliv</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ursocel | Ursodiol | Ursofalk</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ursobilane</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Asopus | Prohepatis | Tatridat | Urdoc | Uruso</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ursofalk | Ursotan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Actigall.1">
<a name="Actigall.1"></a>Actigall (ursodiol) [prescribing information]. Irvine, CA: Allergan; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25366008">
<a name="25366008"></a>Akiyama S, Imamura T, Tamura T, et al. Recurrent common bile duct stones composed of ursodeoxycholic acid: a report of four cases. <i>Intern Med</i>. 2014;53(21):2489-2492. doi:10.2169/internalmedicine.53.2886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/25366008/pubmed" id="25366008" target="_blank">25366008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27892944">
<a name="27892944"></a>Al Jefri AH, Abujazar H, Al-Ahmari A, et al. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management. <i>Bone Marrow Transplant</i>. 2017;52(4):588-591. doi:10.1038/bmt.2016.300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/27892944/pubmed" id="27892944" target="_blank">27892944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23085647">
<a name="23085647"></a>Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to &lt;1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. <i>J Hepatol.</i> 2013;58(2):329-334. doi:10.1016/j.jhep.2012.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/23085647/pubmed" id="23085647" target="_blank">23085647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18223390">
<a name="18223390"></a>Arslanoglu S, Moro GE, Tauschel HD, Boehm G. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. <i>J Pediatr Gastroenterol Nutr.</i> 2008;46(2):228-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/18223390/pubmed" id="18223390" target="_blank">18223390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33273315">
<a name="33273315"></a>Bonifazi F, Sica S, Angeletti A, et al. Veno-occlusive disease in HSCT patients: consensus-based recommendations for risk assessment, diagnosis, and management by the GITMO group. <i>Transplantation</i>. 2021;105(4):686-694. doi:10.1097/TP.0000000000003569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/33273315/pubmed" id="33273315" target="_blank">33273315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36083140">
<a name="36083140"></a>Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i>. 2023;77(2):659-702. doi:10.1002/hep.32771<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/36083140/pubmed" id="36083140" target="_blank">36083140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9833912">
<a name="9833912"></a>Brites D, Rodrigues CM. Elevated levels of bile acids in colostrum of patients with cholestasis of pregnancy are decreased following ursodeoxycholic acid therapy [see comments]. <i>J Hepatol</i>. 1998;29(5):743-751. doi:10.1016/s0168-8278(98)80255-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9833912/pubmed" id="9833912" target="_blank">9833912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31378395">
<a name="31378395"></a>Chappell LC, Bell JL, Smith A, et al; PITCHES study group. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. <i>Lancet</i>. 2019;394(10201):849-860. doi:10.1016/S0140-6736(19)31270-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/31378395/pubmed" id="31378395" target="_blank">31378395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343182">
<a name="15343182"></a>Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. <i>J Pediatr.</i> 2004;145(3):317-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/15343182/pubmed" id="15343182" target="_blank">15343182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26017019">
<a name="26017019"></a>Cheuk DK, Chiang AK, Ha SY, et al. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.<i> Cochrane Database Syst Rev</i>. 2015;(5):CD009311. doi:10.1002/14651858.CD009311.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/26017019/pubmed" id="26017019" target="_blank">26017019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2391610">
<a name="2391610"></a>Colombo C, Setchell KD, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. <i>J Pediatr.</i> 1990;117(3):482-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2391610/pubmed" id="2391610" target="_blank">2391610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21658639">
<a name="21658639"></a>Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. <i>J Cyst Fibros.</i> 2011;10 Suppl 2:S29-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21658639/pubmed" id="21658639" target="_blank">21658639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16842466">
<a name="16842466"></a>De Marco G, Sordino D, Bruzzese E, et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. <i>Aliment Pharmacol Ther</i>. 2006;24(2):387-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/16842466/pubmed" id="16842466" target="_blank">16842466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24102514">
<a name="24102514"></a>Dignan FL, Wynn RF, Hadzic N, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. <i>Br J Haematol</i>. 2013;163(4):444-457. doi:10.1111/bjh.12558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24102514/pubmed" id="24102514" target="_blank">24102514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770681">
<a name="10770681"></a>Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. <i>Turk J Pediatr.</i> 1999;41(1):91-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10770681/pubmed" id="10770681" target="_blank">10770681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erol-Coskun.1">
<a name="Erol-Coskun.1"></a>Erol-Coskun H, Karagur N, Akyol F et al. Ursodiol use during breastfeeding: a case report. <i>Reprod Toxicol</i>. 2018;80:59. Abstract. doi:10.1016/j.reprotox.2018.07.070</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738507">
<a name="35738507"></a>European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on sclerosing cholangitis. <i>J Hepatol</i>. 2022;77(3):761-806. doi:10.1016/j.jhep.2022.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/35738507/pubmed" id="35738507" target="_blank">35738507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30266674">
<a name="30266674"></a>Faraci M, Bertaina A, Luksch R, et al. Sinusoidal obstruction syndrome/veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. <i>Biol Blood Marrow Transplant</i>. 2019;25(2):313-320. doi:10.1016/j.bbmt.2018.09.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/30266674/pubmed" id="30266674" target="_blank">30266674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24421907">
<a name="24421907"></a>Geenes V, Lövgren-Sandblom A, Benthin L, et al. The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. <i>PLoS One</i>. 2014;9(1):e83828. doi:10.1371/journal.pone.0083828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24421907/pubmed" id="24421907" target="_blank">24421907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21566568">
<a name="21566568"></a>Gokmen T, Oguz SS, Bozdag S, Erdeve O, Uras N, Dilmen U. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. <i>J Perinatol.</i> 2012;32(2):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21566568/pubmed" id="21566568" target="_blank">21566568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25982180">
<a name="25982180"></a>Guo GY, Shi YQ, Wang L, et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. <i>Aliment Pharmacol Ther</i>. 2015;42(2):221-30. doi: 10.1111/apt.13244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/25982180/pubmed" id="25982180" target="_blank">25982180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hassan.1">
<a name="Hassan.1"></a>Hassan H, Balistreri WF. Neonatal cholestasis. In: Kliegman RM, Geme JS, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap 383.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1619357">
<a name="1619357"></a>Hofmann AF, Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. <i>J Lipid Res</i>. 1992;33(5):617-626.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/1619357/pubmed" id="1619357" target="_blank">1619357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8528836">
<a name="8528836"></a>Johnson CE, Nesbitt J. Stability of ursodiol in an extemporaneously compounded oral liquid. <i>Am J Health Syst Pharm</i>. 1995;52(16):1798-1800.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/8528836/pubmed" id="8528836" target="_blank">8528836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22670841">
<a name="22670841"></a>Kappler M, Espach C, Schweiger-Kabesch A, et al. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study. <i>Aliment Pharmacol Ther</i>. 2012;36(3):266-273. doi:10.1111/j.1365-2036.2012.05177.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/22670841/pubmed" id="22670841" target="_blank">22670841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878208">
<a name="17878208"></a>Kelly DA, Davenport M. Current management of biliary atresia. <i>Arch Dis Child.</i> 2007;92(12):1132-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/17878208/pubmed" id="17878208" target="_blank">17878208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143129">
<a name="16143129"></a>Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. <i>Gastroenterology</i>. 2005;129(3):894-901. doi:10.1053/j.gastro.2005.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/16143129/pubmed" id="16143129" target="_blank">16143129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27749550">
<a name="27749550"></a>Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study) [published correction appears in <i>Medicine (Baltimore)</i>. 2017;96(3):e6031]. <i>Medicine (Baltimore)</i>. 2016;95(40):e4949. doi:10.1097/MD.0000000000004949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/27749550/pubmed" id="27749550" target="_blank">27749550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21809485">
<a name="21809485"></a>Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. <i>Clin Res Hepatol Gastroenterol</i>. 2011;35(2):89-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21809485/pubmed" id="21809485" target="_blank">21809485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33197417">
<a name="33197417"></a>Lee RH, Greenberg M, Metz TD, Pettker CM; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine consult series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011. <i>Am J Obstet Gynecol.</i> 2021;224(2):B2-B9. doi:10.1016/j.ajog.2020.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/33197417/pubmed" id="33197417" target="_blank">33197417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9003851">
<a name="9003851"></a>Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. <i>J Pediatr.</i> 1997;130(1):52-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9003851/pubmed" id="9003851" target="_blank">9003851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10417972">
<a name="10417972"></a>Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. <i>J Pediatr Endocrinol Metab.</i> 1999;12(4):549-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10417972/pubmed" id="10417972" target="_blank">10417972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394-419. doi:10.1002/hep.30145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9041099">
<a name="9041099"></a>Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. <i>N Engl J Med</i>. 1997;336(10):691-695. doi:10.1056/NEJM199703063361003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9041099/pubmed" id="9041099" target="_blank">9041099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353641">
<a name="23353641"></a>Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. <i>Clin Gastroenterol Hepatol.</i> 2013;11(7):841-846. doi:10.1016/j.cgh.2012.12.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/23353641/pubmed" id="23353641" target="_blank">23353641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34988851">
<a name="34988851"></a>Liu SY, Chang LW, Wang J, Xie M, Chen LL, Liu W. Ursodeoxycholic acid prevention on cholestasis associated with total parenteral nutrition in preterm infants: a randomized trial. <i>World J Pediatr</i>. 2022;18(2):100-108. doi:10.1007/s12519-021-00487-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/34988851/pubmed" id="34988851" target="_blank">34988851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889240">
<a name="28889240"></a>Magouliotis DE, Tasiopoulou VS, Svokos AA, et al. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: an updated systematic review and meta-analysis. <i>Obes Surg</i>. 2017;27(11):3021-3030. doi:10.1007/s11695-017-2924-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/28889240/pubmed" id="28889240" target="_blank">28889240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31214465">
<a name="31214465"></a>Mahadeo KM, Bajwa RPS. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>J Pediatr Intensive Care</i>. 2014;3(3):183-193. doi:10.3233/PIC-14102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/31214465/pubmed" id="31214465" target="_blank">31214465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31818728">
<a name="31818728"></a>Mahadeo KM, Bajwa R, Abdel-Azim H, et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematol</i>. 2020;7(1):e61-e72. doi:10.1016/S2352-3026(19)30201-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/31818728/pubmed" id="31818728" target="_blank">31818728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34746509">
<a name="34746509"></a>Matsui H, Yoshida T, Homma S, et al. Ursodeoxycholic acid triggers primary enterolith growth in a crohn's disease patient with jejunal stenosis. <i>J Anus Rectum Colon</i>. 2021;5(4):433-438. doi:10.23922/jarc.2021-017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/34746509/pubmed" id="34746509" target="_blank">34746509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12632357">
<a name="12632357"></a>Meyers RL, Books LS, O’Gorman MA, et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. <i>J Pediatr Surg.</i> 2003;38(3):406-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/12632357/pubmed" id="12632357" target="_blank">12632357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25091893">
<a name="25091893"></a>Mukai S, Onoe T, Tashiro H, Ohdan H. Small bowel obstruction due to an unconjugated ursodeoxycholic acid enterolith following living donor liver transplantation: Report of a case. <i>Hepatol Res</i>. 2015;45(7):818-822. doi:10.1111/hepr.12401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/25091893/pubmed" id="25091893" target="_blank">25091893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9443120">
<a name="9443120"></a>Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. <i>J Pediatr Gastroenterol Nutr.</i> 1998;26(1):49-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9443120/pubmed" id="9443120" target="_blank">9443120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2730950">
<a name="2730950"></a>Nittono H, Tokita A, Hayashi M, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. <i>Biomed Pharmacother</i>. 1989;43(1): 37-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2730950/pubmed" id="2730950" target="_blank">2730950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16285948">
<a name="16285948"></a>Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. <i>Gastroenterology</i>. 2005;129(5):1464-1472. doi:10.1053/j.gastro.2005.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/16285948/pubmed" id="16285948" target="_blank">16285948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33915090">
<a name="33915090"></a>Ovadia C, Sajous J, Seed PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. <i>Lancet Gastroenterol Hepatol.</i> Published online April 26, 2021. doi:10.1016/S2468-1253(21)00074-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/33915090/pubmed" id="33915090" target="_blank">33915090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27493115">
<a name="27493115"></a>Parízek A, Simják P, Cerný A, et al. Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. <i>Ann Hepatol</i>. 2016;15(5):757-761. doi:10.5604/16652681.1212562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/27493115/pubmed" id="27493115" target="_blank">27493115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35468945">
<a name="35468945"></a>Pennesi E, Michels N, Brivio E, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. <i>Leukemia</i>. 2022;36(6):1516-1524. doi:10.1038/s41375-022-01576-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/35468945/pubmed" id="35468945" target="_blank">35468945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reltone.1">
<a name="Reltone.1"></a>Reltone (ursodiol) [prescribing information]. Las Vegas, NV: Intra-Sana Laboratories LLC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10651838">
<a name="10651838"></a>Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. <i>Eur J Clin Invest</i>. 2000;30(2):135-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10651838/pubmed" id="10651838" target="_blank">10651838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32091825">
<a name="32091825"></a>Ruutu T, Carreras E. Hepatic complications. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. <i>The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies</i>. 7th ed. Cham (CH): Springer; 2019.373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/32091825/pubmed" id="32091825" target="_blank">32091825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12200355">
<a name="12200355"></a>Ruutu T, Eriksson B, Remes K, et al; Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. <i>Blood</i>. 2002;100(6):1977-1983. doi:10.1182/blood-2001-12-0159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/12200355/pubmed" id="12200355" target="_blank">12200355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24141008">
<a name="24141008"></a>Ruutu T, Juvonen E, Remberger M, et al; Nordic Group for Blood and Marrow Transplantation. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. <i>Biol Blood Marrow Transplant</i>. 2014;20(1):135-138. doi:10.1016/j.bbmt.2013.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24141008/pubmed" id="24141008" target="_blank">24141008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26817509">
<a name="26817509"></a>Sepúlveda Marín S, Contreras Maragaño V, Vera C. Is ursodeoxycholic acid effective for intrahepatic cholestasis of pregnancy? <i>Medwave</i>. 2016;16(Suppl 1):e6361. doi:10.5867/medwave.2015.6361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/26817509/pubmed" id="26817509" target="_blank">26817509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30357607">
<a name="30357607"></a>Shen Y, Zhou J, Zhang S, et al. Is it necessary to perform the pharmacological interventions for intrahepatic cholestasis of pregnancy? A bayesian network meta-analysis. <i>Clin Drug Investig</i>. 2019;39(1):15-26. doi:10.1007/s40261-018-0717-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/30357607/pubmed" id="30357607" target="_blank">30357607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9934970">
<a name="9934970"></a>Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. <i>J Pediatr Gastroenterol Nutr.</i> 1999;Suppl 1:S1-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9934970/pubmed" id="9934970" target="_blank">9934970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8780577">
<a name="8780577"></a>Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. <i>Gastroenterology.</i> 1996;111(3):717-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/8780577/pubmed" id="8780577" target="_blank">8780577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21251891">
<a name="21251891"></a>Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. <i>Dig Liver Dis</i>. 2011;43(4):309-313. doi:10.1016/j.dld.2010.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21251891/pubmed" id="21251891" target="_blank">21251891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17706489">
<a name="17706489"></a>Stringer MD, Davison SM, Rajwal SR, McClean P. Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. <i>J Pediatr Surg.</i> 2007;42(8):1324-1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/17706489/pubmed" id="17706489" target="_blank">17706489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17241926">
<a name="17241926"></a>Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2007;13(2):206-217. doi:10.1016/j.bbmt.2006.09.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/17241926/pubmed" id="17241926" target="_blank">17241926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24782691">
<a name="24782691"></a>Thibault M, McMahon J, Faubert G, et al. Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates. <i>J Pediatr Pharmacol Ther</i>. 2014;19(1):42-48. doi:10.5863/1551-6776-19.1.42<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24782691/pubmed" id="24782691" target="_blank">24782691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26832651">
<a name="26832651"></a>Tran TT, Ahn J, Reau NS. ACG clinical guideline: liver disease and pregnancy [published correction appears in <i>Am J Gastroenterol</i>. 2016;111(11):1668]. <i>Am J Gastroenterol</i>. 2016;111(2):176-194. doi:10.1038/ajg.2015.430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/26832651/pubmed" id="26832651" target="_blank">26832651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2890915">
<a name="2890915"></a>Ullrich D, Rating D, Schroter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. <i>Lancet.</i> 1987;2(8571):1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2890915/pubmed" id="2890915" target="_blank">2890915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Urso250UrsoForte.2">
<a name="Urso250UrsoForte.2"></a>Urso 250 and Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UrsoUrsoDS.1">
<a name="UrsoUrsoDS.1"></a>Urso and Urso DS (ursodiol) [product monograph]. Mont-St-Hilaire, Quebec, Canada: Aptalis Pharma Canada Inc; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Urso.1">
<a name="Urso.1"></a>Urso tablets (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc; June 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Urso.1">
<a name="Urso.1"></a>Ursodiol capsules, USP [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20619755">
<a name="20619755"></a>Vítek L, Zelenková M, Brůha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. <i>Dig Liver Dis</i>. 2010;42(12):911-912. doi:10.1016/j.dld.2010.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/20619755/pubmed" id="20619755" target="_blank">20619755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24696095">
<a name="24696095"></a>Wales PW, Allen N, Worthington P, George D, Compher C; American Society for Parenteral and Enteral Nutrition, Teitelbaum D. A.S.P.E.N. clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease. <i>JPEN J Parenter Enteral Nutr</i>. 2014;38(5):538-557. doi:10.1177/0148607114527772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24696095/pubmed" id="24696095" target="_blank">24696095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716060">
<a name="32716060"></a>Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. <i>Cochrane Database Syst Rev.</i> 2020;7(7):CD000493. doi:10.1002/14651858.CD000493.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/32716060/pubmed" id="32716060" target="_blank">32716060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Warner.1">
<a name="Warner.1"></a>Warner S, Kelly DA. Liver failure. In: Wyllie R, Hyams J, Kay M, eds. <i>Pediatric Gastrointestinal and Liver Disease</i>. 6th ed. Elsevier; 2021:chap 77.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19029197">
<a name="19029197"></a>Willot S, Uhlen S, Michaud L, et al. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. <i>Pediatrics</i>. 2008;122(6):e1236-e1241. doi:10.1542/peds.2008-0986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/19029197/pubmed" id="19029197" target="_blank">19029197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30130826">
<a name="30130826"></a>Wong ZH, Davenport M. What happens after Kasai for biliary atresia? A European multicenter survey. <i>Eur J Pediatr Surg</i>. 2019;29(1):1-6. doi:10.1055/s-0038-1668146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/30130826/pubmed" id="30130826" target="_blank">30130826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24519384">
<a name="24519384"></a>Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. <i>Hepatology</i>. 2014;60(3):931-940. doi:10.1002/hep.27074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/24519384/pubmed" id="24519384" target="_blank">24519384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201513">
<a name="8201513"></a>Yamashiro Y, Ohtsuka Y, Shimizu T. Effects of ursodeoxycholic acid treatment on essential fatty acid deficiency in patients with biliary atresia. <i>J Pediatr Surg.</i> 1994;29(3):425-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/8201513/pubmed" id="8201513" target="_blank">8201513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799965">
<a name="27799965"></a>Zhang Y, Lu L, Victor DW, Xin Y, Xuan S. Ursodeoxycholic acid and S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: a meta-analysis. <i>Hepat Mon</i>. 2016;16(8):e38558. doi:10.5812/hepatmon.38558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/27799965/pubmed" id="27799965" target="_blank">27799965</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12872 Version 366.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
